Gestion des Achats et de la Logistique des Médicaments et des Produits VIH/SIDA Addis Ababa / Ethiopie 24 Février 2005
|
|
|
- Elvin Whitehead
- 7 years ago
- Views:
Transcription
1 Gestion des Achats et de la Logistique des Médicaments et des Produits VIH/SIDA Addis Ababa / Ethiopie 24 Février 2005 Stockage, SIGL, Gestion de Stock et Distribution
2 LE CYCLE LOGISTIQUE POLITIQUE Service Clients Contrôle Qualité Contrôle Qualité Gestion de Stock Stockage Distribution Système d Information de Gestion Logistique (SIGL) Suivi Organisation & Personnel Budget Supervision Evaluation Sélection des Produits Contrôle Qualité Contrôle Qualité Prévisions & Acquisition ADAPTABILITE
3 Points Principaux de la Journée Stockage SIGL Contrôle des Stocks Tous font partis de la gestion de stock!
4 Points Essentiels Systèmes intégrés ou systèmes verticaux. Pleine disponibilité ou approvisionnement limitée en produits.
5 But du Stockage Protèger la qualité du produit et son emballage tout au long de la chaîne d approvisionnement. Rendre le produit disponible pour la distribution.
6 Exemple : le Kaletra Stockées à 25ºC, les capsules de Kaletra sont stable et efficaces pendant 2 mois. Pour un stockage d un jour à 45 C > les capsules deviennent molles, collantes et se délitent en les séparant. Recommandation d Abbott : ne pas fournir plus de 30 jours d approvisionnement en climat chaud.
7 Exemple : Determine Stockage entre 2ºC et 30ºC Le chase buffer expire au bout de mois Le test expire au bout de mois
8 2 décisions clé du SIGL Quelles données collecter Quel doit être le format du SIGL
9 3 données essentielles Stock disponible Taux de consommation Pertes et Ajustements
10 Facility Name Revised 3/2003 ORIGINAL MINISTRY OF HEALTH MONTHLY REPORT & REQUEST FOR LABORATORY REAGENTS District: Province: Revised 3/2003 TRIPLICATE MINISTRY OF HEALTH MONTHLY REPORT & REQUEST FOR LABORATORY REAGENTS Facility Name District: Province: Facility Type: Laboratory Other Managed by: GOK NGO Private Facility Type: Laboratory Other Managed by: GOK NGO Private Report of Period Beginning 20 Ending 20 Report of Period Beginning 20 Ending 20 Table 1: Monthly Total Quantities Used by Each Type of Service Reagent Name Unit Pack Clinical Diagnois Blood Screening VCT PMTCT Other Total s Reagent Name Unit Pack Begining Balance A B C D E F G H Receive d This Period Total s Used Total s Issued Adjustm ents (*) Physic al Count Earliest expiry date of stock Qty Needed Determine Date Qty Unigold InstantScreen Other Enzygnost Determine Unigold Instant Screen Other Vironostika Other Hep B SAH Murex Anti HCV Other RPR Other Total # Total # Clients s Table 2: Status of ing Equipment, Storage Facility and Trained Personnel Type of Machine, Equipment Date of Last Service Number of trained staff Condition/Comments Enzygnost Vironostika Other Hep B SAH Murex Anti HCV Other RPR Others Comments: Submitted by: Name Signature Designation: Date: * - In Column E put (E) for Expired, (W) for Withdrawn, (A) for Stock Adjustment or (O) for Other
11 MONTHLY FACILITY REPORT OF HIV TEST USAGE Ministry of Health / Ghana Health Services Republic of Ghana Facility Name: Report Period: District: Region: Date Prepared For each test type, include tests used for initial screening, confirmatory tests, and tie-breaker tests (if applicable). month/year day/month/year Note: Re-supply quantities are based on the number of tests used during the month/quarter. Under-reporting the number of tests used will result in insufficient re-supply and could lead to stock outs at the testing facility. Item Description ( Type) Rapid Assay HIV Kits Blood Safety Voluntary Counseling and ing (VCT) Client/Patient ing Prevention of Mother to Child Transmission (PMTCT) Clinical Diagnosis Sentinel Surveillance Lab Controls Facility Use Quality ing A B C D E F G H ing Wastage Total Number of s Used during the Month I = A + B + C + D + E + F + G + H Stock on Hand at the End of the Month J Determine HIV 1/2 (Abbot) Rapi- HIV 1/2 Long ELISA HIV Kits Vironostika Uniform II HIV 1/2 plus O (Organon) Remarks: Prepared by: Name/Signature: Designation: Date: Reviewed by: Name/Signature: Designation: Date:
12 MONTHLY REPORT FOR HIV TEST KITS AND CONSUMABLE LABORATORY SUPPLIES FOR HIV TESTING Ministry of Health / Ghana Health Services Republic of Ghana Region: Report Period: month/year Maximum Stock Level: 3 Months Date Prepared day/month/year Serial No. Item Description No. s per Kit Basic Unit Rapid Assay HIV TEST KITS 1 Determine HIV 1/2 (Abbot) test 2 Rapi- HIV 1/ test 3 1 test Opening Balance Total Qty. Received during the Month Total Monthly Issues Losses/ Adjustments (+ / -) A B C D Closing Balance E = A + B C +/- D Months of Stock on Hand F = E/C Total No. Days Out of Stock G ELISA HIV Kits 4 Vironostika Uniform II HIV 1/2 plus O (Organon) test 5 1 test Consumable Laboratory Supplies for HIV ing 6 Pipette Tips (Small) 5-40 microliter (venipuncture) 7 Pipette Tips (Big) microliter (venipuncture) 8 Pasteur Pipettes graduated with bulb, Non-Sterile 9 Disposable Plastic [for venipuncture assay] 10 Vacutainers - 10ml 11 Vacutainer plain/serum Tubes 4 ml [plastic] 12 Vacutainer multi-sampler 21 Gauge needles Remarks: Prepared by: Name/Signature: Designation: Date: Name/Signature: Designation: Date: Reviewed by: Name/Signature: Designation: Date:
13 MONTHLY LOGISTICS AND NEW PATIENTS REPORT JCRC FREE DRUGS Facility Name: Report Period: Maximum Stock Level 2 months District: month/year Delivery Zone: Date Prepared Minimum Stock Level 1month day/month/year Serial No. Drug Product 1 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS REPORT Basic Unit 1 Zidovudine (AZT, ZDV) 100mg Capsule 2 Zidovudine (AZT, ZDV) 300mg Tablet 3 Zidovudine (AZT, ZDV) 10mg/ml oral solution Btl 240ml Opening Balance Total Qty. Received during the Month Total Monthly Consumption Losses/ Adjustments ( +/- ) Closing Balances Facility Stores + Dispensing Area E = A + B - C +/- D NEW PATIENTS Estimated number of NEW patients on this drug for next month A B C D E F 4 Lamivudine (3TC) 150mg Tablet 5 Lamivudine (3TC) 10mg/ml oral solution Btl 240ml 6 Stavudine (D4T) 20mg Capsule 7 Stavudine (D4T) 30mg Capsule 8 Stavudine (D4T) 40mg Capsule 9 Didanosine (DDI) 25mg Tablet 10 Didanosine (DDI) 100mg Tablet 11 Didanosine (DDI) 200mg Tablet
14 Republic of Ghana Ministry of Health/Ghana Health Services MONTHLY LMIS REPORT FOR ANTIRETROVIRAL DRUGS Facility: Central Medical Stores TEMA Month/Year: Maximum Stock Level: 10 Months Region : Greater Accra Region Minimum Stock Level: 7 Months A B C1 C2 D E F G H I J CMS CMS CMS ART Sites CMS CMS CMS CMS CMS MAXIMUM QUANTITY TOTAL Total Total MONTHS STOCK TO ORDER TOTAL TOTAL TOTAL Losses/ CLOSING Quantity No. Days OF STOCK QUANTITY QUANTITY UNIT [Rounded up Serial Basic OPENING QUANTITY QUANTITY MONTHLY Adjustments BALANCE 2 to Expire in Out of ON HAND 3 (C2 x Maximum TO ORDER PACK to Pack Size) No. Drug Product Unit BALANCE RECEIVED ISSUED 1 ONSUMPTIO (+ / -) A+B-C1(+/-D) 3 Months Stock ( E / C2 ) Stock Level) ( G - E ) SIZE ( H / J ) FIXED DOSE COMBINATIONS 1 Zidovudine 300mg/Lamivudine 150mg Tablet 60 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 2 Nevirapine (NVP) 50mg/5ml oral suspension (BI) 240ml Bottle 1 3 Nevirapine (NVP) 10mg/ml oral suspension (BI) 20ml Bottle 1 4 Nevirapine (NVP) 200mg Tablet 60 5 Efavirenz (EFV) 30mg/ml syrup???ml Bottle 1 6 Efavirenz (EFV) 50mg Capsule 30 7 Efavirenz (EFV) 100mg Capsule 30 8 Efavirenz (EFV) 200mg Capsule 90 9 Efavirenz (EFV) 600mg Tablet 30 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 10 Zidovudine (AZT) 10mg/ml syrup 200ml Bottle 1 11 Zidovudine (AZT) 100mg Capsule Zidovudine (AZT) 300mg Tablet Lamivudine (3TC) 10mg/ml oral solution 240ml Bottle 1 14 Lamivudine (3TC) 150mg Tablet Stavudine (d4t) 1mg/ml PFR for oral sol 200mg/Bottle 1 16 Stavudine (d4t) 15mg Capsule Stavudine (d4t) 20mg Capsule Stavudine (d4t) 30mg Capsule Stavudine (d4t) 40mg Capsule Didanosine (ddi) 10mg/ml oral sol 2Gm PFR 4oz Bottle 1 21 Didanosine (ddl) 25mg Tablet Didanosine (ddl) 50mg Tablet Didanosine (ddl) 100mg Tablet Didanosine (ddi) 150mg Tablet Didanosine (ddi) 200mg Tablet Abacavir (ABC) 20mg/ml oral sol 240ml Bottle 1 27 Abacavir (ABC) 300mg Tablet 60 NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR 28 Tenofovir (TFD) 300mg Tablet 30 PROTEASE INHIBITORS 29 Nelfinavir Mesylate (NFV) 50mg/g PFR 144g/Bottle 1 [50mg per 1.25ml scoop] 30 Nelfinavir Mesylate (NFV) 250mg Tablet Lopinavir+Ritonavir (LPV/r) 400mg/100mg/5ml 300ml Bottle 1 32 Lopinavir+Ritonavir (LPV/r) 133.3mg/33.3mg Capsule The Total Quantity Issued from CMS during the month (Column C1) should equal the sum of the Total Quantity Received by all ART Facilities during the month. 2 The Closing Balance at CMS is calculated by subtracting the Total Quantity Issued (Column C1) during the month. 3 The Months of Stock on Hand at CMS is calculated using the Total Monthly Consumption at all ART sites (Column C2).
15 Monthly Summary Report of ART Patients Facility: District: Region: Republic of Ghana Ministry of Health/Ghana Health Service DRAFT for review JSI/DELIVER Nov 2004 Month: Year: A A1 A2 A3 A4 A5 A6 B B1 B2 B3 B4 B5 B6 B7 B8 B9 Treatment Regimen ADULT 1st Line Regimens AZT 300mg/3TC 150mg + NVP 200mg AZT 300mg/3TC 150mg + EFV 600mg d4t(30) + 3TC 150mg + NVP 200mg d4t(40) + 3TC 150mg + NVP 200mg d4t(30) + 3TC 150mg + EFV 600mg d4t(40) + 3TC 150mg + EFV 600mg ADULT 2nd Line Regimens TDF 300mg + ddi 250mg + NFV 250mg TDF 300mg + ddi 250mg + LPV/r 133.3mg/33.3mg ABC 300mg + ddi 150mg + NFV 250mg (< 60kg) ABC 300mg + ddi 200mg + NFV 250mg (> 60kg) ABC 300mg + ddi 150mg + LPV/r 133.3mg/33.3mg (< 60kg) ABC 300mg + ddi 200mg + LPV/r 133.3mg/33.3mg (> 60kg) ADULT Other Regimens AZT 300mg/3TC 150mg + NFV 250mg AZT 300mg/3TC 150mg + ABC 300mg AZT 300mg + ddi 150mg +NFV 250mg (< 60kg) No. Patients on Regimen No. of New Patients No of shifts during the month Total No. Patients on at Beginning on Regimen To From Regimen at of Month end of Month regimen regimen end of Month A B C D E = (A+B+C)-D B10 AZT 300mg + ddi 200mg + NFV 250mg (> 60kg) B11 d4t(30) + 3TC 150mg + NFV 250mg (< 60kg) B12 d4t(40) + 3TC 150mg + NFV 250mg (> 60kg) B13 d4t(30) + 3TC 150mg + LPV/r 133.3mg/33.3mg (< 60kg) B14 d4t(40) + 3TC 150mg + LPV/r 133.3mg/33.3mg (> 60kg) B15 d4t(30) + 3TC 150mg + ddi 150mg (< 60kg) B16 d4t(40) + 3TC 150mg + ddi 200mg (> 60kg) B17 d4t(30) + ddi 150mg + EFV 600mg (< 60kg) B18 d4t(40) + ddi 200mg + EFV 600mg (> 60kg) B19 ddi 150mg + 3TC 150mg + NFV 250mg (< 60kg) B20 ddi 200mg + 3TC 150mg + NFV 250mg (> 60kg)
16 But du contrôle de stock Maintenir un niveau de stock approprié de tous les produits, en évitant les pénuries et les sur-stockages.
17 Exemple simplifié de Chaîne d Approvisionnement PORT Entrepôt Central Entrepôt Régional Hôpital de District Centre de Santé Dispensaire Agent de Santé Communautaire CLIENTS
Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ emtricitabine/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ emtricitabine/
Comprehensive Case Management Reassessment
Comprehensive Case Management Reassessment Reassessment Date: Date of previous Assessment/Reassessment: Name: Client ID # Address: If Reassessment early or late explain: Current HIV Status: Asymptomatic
HIV 1. A reference guide for prescription HIV-1 medications
HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in
Antiretroviral therapy for HIV infection in infants and children: Towards universal access
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
Foreword... 2 Acknowledgements... 3. Background of AIDSRelief ART Supply Chain Management... 8
SUPPLY CHAIN MANUAL Foreword The AIDSRelief health supply chain management manual was written in response to field requests for support in building and maintaining sustainable health supply chain management
CDC occupation Codes used to code ( map ) facility locations
CDC occupation Codes used to code ( map ) facility locations CDC (occupation) Code BLS SOC (2000)* CDC (occupation) Code BLS SOC (2000)* ATT-Attendant/orderly 31-1012 CLA-Clerical/administrative CNA-Nurse
THE GOVERNMENT OF KENYA MINISTRY OF HEALTH FACILITY
THE GOVERNMENT OF KENYA MINISTRY OF HEALTH FACILITY CONSUMPTION DATA REPORT AND REQUEST (F-CDRR) FOR FOR ANTIRETROVIRAL AND OPPORTUNISTIC INFECTION MEDICINES STANDALONE SITES Facility name: Facility code:
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS. Weerawat Manosuthi
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS Weerawat Manosuthi Outline Case scenario of postexposure prophylaxis Risks of and how to manage postexposure prophylaxis Current PEP guideline US PHS 2013 New York
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
Treatment Information Service 1 800 HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition
HIV/AIDS Treatment Information Service 1 800 HIV 0440 HIV and Its Treatment What You Should Know 2nd edition HIV/AIDS TREATMENT INFORMATION SERVICE 2nd Edition HIV and Its Treatment: What You Should Know
Chapter 3 South African guidelines and introduction to clinical cases
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013 VERSION 14 March 2013 Contents Acronym glossary... 2 1. Goals of the programme... 3 2. Objectives... 3 3. Specific Objectives... 3 4. Adults and
Paediatric HIV treatment update
Paediatric HIV treatment update James Nuttall Red Cross War Memorial Children s Hospital & University of Cape Town ART Resistance & New Treatment Options 6 th FIDSSA Conference, 5-7 November 2015 ART Eligibility
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS Stefano Vella Dipartimento del Farmaco Istituto Superiore di Sanità - Roma Stages of HIV-1 Life Cycle Targeted by Anti-HIV Drugs In: Gulick RM, Topics HIV
AIDS ACCESS FOUNDATION/ MSF AIDS can be Treated: A handbook of Antiretroviral medicines. AIDS Can Be Treated. A Hand Book of Antiretroviral medicines
AIDS Can Be Treated A Hand Book of Antiretroviral medicines The translation of this booklet is due to support from the Working Together Regional Training Project of the AIDS Access Foundation, Bangkok
Blood/Bodily Fluid Exposure and Needlestick Injury Policy Statement & HIV PEP Kit Dispensing Guideline
Blood/Bodily Fluid Exposure and Needlestick Injury Policy Statement & HIV PEP Kit Dispensing Guideline Providing certain services in a pharmacy, especially injections, carries a risk for the pharmacist
PEP Step 2: Report and Document
RISK The risk of exposure to blood and bloodborne pathogens is slightly greater for health care personnel (HCP) than for people who do not work around blood. An exposure to infected blood, tissue, or other
HIV. Head - Paediatric HIV Treatment Programmes. Right to Care. Dr Leon Levin
HIV Dr Leon Levin Head - Paediatric HIV Treatment Programmes Right to Care Disclaimer This talk represents my personal experience in managing teenagers with HIV over the last 14 years. It does not purport
The Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and
The Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and Adults. 2015 (Amended Version) The Western Cape Consolidated
Drug Treatment Program Update
Drug Treatment Program Update As of May 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
Quantification of Health Commodities
Quantification of Health Commodities A Guide to Forecasting and Supply Planning for Procurement JUNE 2014 This publication was produced for review by the U.S. Agency for International Development. It was
Nelfinavir: Where are we now? Experience in Ghana
Nelfinavir: Where are we now? Experience in Ghana Delese Mimi Darko Head, Drug Evaluation and Registration Food and Drugs Board 13 th ICDRA, September,2008 Berne, Switzerland Outline HIV/AIDS The Ghanaian
Management of HIV and TB Co-infection in South Africa
Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy
Myths and Realities on Prices of AIDS Drugs
White Paper Myths and Realities on Prices of AIDS Drugs by Carol C. Adelman, Dr.P.H., Senior Fellow Jeremiah Norris, Adjunct Fellow S. Jean Weicher, Research Assistant Introduction: The introduction of
National Antiretroviral Treatment Guidelines
National Antiretroviral Treatment Guidelines Copyright 2004 Department of Health Published by Jacana Printed by Minuteman Press ISBN: 1-919931-69-4 National Department of Health South Africa 2004 This
Bioequivalence Study Design Considerations. Dr. John Gordon
Bioequivalence Study Design Considerations Dr. John Gordon Key Output of Programme A list of prequalified medicinal products used for treatment of HIV/AIDS, malaria, tuberculosis, influenza, and for reproductive
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa T. Sonia Boender; Raph L. Hamers; Pascale Ondoa; Maureen Wellington; Cleophas Chimbetete; Margaret Siwale; Eman E F
Antiretroviral Treatment
Antiretroviral Treatment Michael A. Tolle, MD, MPH Heidi Schwarzwald, MD, MPH Nancy R. Calles, MSN, PNP, ACRN, MPH Objectives 1. Discuss the goals of treatment for human immunodeficiency virus (HIV) infection.
MANAGEMENT OF HIV & AIDS COMMODITIES IN ZIMBABWE
MANAGEMENT OF HIV & AIDS COMMODITIES IN ZIMBABWE A CAPACITY ASSESSMENT OF NATPHARM AND MINISTRY OF HEALTH AND CHILD WELFARE JULY 2006 This publication was produced for review by the United States Agency
Paediatric HIV Drug Resistance in African Settings
Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV
Benin Tourist visa Application
Benin Tourist visa Application Please enter your contact information Name: Email: Tel: Mobile: The latest date you need your passport returned in time for your travel: Benin tourist visa checklist Filled
GENERAL INSTRUCTIONS FOR COMPLETING THE HIV TEST FORM
GENERA INSTRUCTIONS FOR COMPETING THE This form is designed to be read by an Optical Character Recognition (OCR) scanner. The legibility of this form depends on the quality of the a hand written and selected
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
ANTIRETROVIRAL DRUGS FOR TREATING PREGNANT WOMEN AND PREVENTING HIV INFECTION IN INFANTS
ANTIRETROVIRAL DRUGS FOR TREATING PREGNANT WOMEN AND PREVENTING HIV INFECTION IN INFANTS GUIDELINES ON CARE, TREATMENT AND SUPPORT FOR WOMEN LIVING WITH HIV/AIDS AND THEIR CHILDREN IN RESOURCE-CONSTRAINED
July 3, 2015. III. VA policy:
Antiretroviral Postexposure Prophylaxis After Sexual, Injection- Drug Use, or Other Nonoccupational Exposure to HIV (nonoccupational post- exposure prophylaxis [npep]) VA Greater Los Angeles Healthcare
Pediatric. Guidelines
Pediatric Antiretroviral Therapy (ART) Guidelines Pediatric Antiretroviral Therapy (ART) Guidelines 4 Pediatric Guidelines 2013 Acknowledgements We knowledge the valuable contributions made by technical
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
r 2006 British HIV Association HIV Medicine (2006), 7, 487 503 British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) B Gazzard on behalf
Nevirapine, zidovudine and lamivudine
nevirapine, zidovudine, lamivudine: 1 nevirapine, zidovudine and lamivudine fixed dose ART combination for treatment of HIV infection Nevirapine, zidovudine and lamivudine Slide 1 nevirapine, zidovudine,
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example Prof. Dr. rer. nat. habil. Harald G. Schweim President Federal Institute
Minimum costs to produce treatments for HIV, Hepatitis B/C and cancer. Dr Andrew Hill, Pharmacology and Therapeutics, Liverpool University, UK
Minimum costs to produce treatments for HIV, Hepatitis B/C and cancer Dr Andrew Hill, Pharmacology and Therapeutics, Liverpool University, UK Africa, 1999: mass treatment for HIV/AIDS is not feasible 2
HIV Care and Antiretroviral Therapy Guidelines Second Edition
HIV Care and Antiretroviral Therapy Guidelines Second Edition Fiji Ministry of Health 2013 1 ii 2 HIV Care and Antiretroviral Therapy Guidelines Second Edition 3 Fiji Ministry of Health 2013 Disclaimer
TREATMENT OF AIDS GUIDELINES FOR THE USE OF ANTIRETROVIRAL THERAPY IN MALAWI
TREATMENT OF AIDS GUIDELINES FOR THE USE OF ANTIRETROVIRAL THERAPY IN MALAWI First Edition October 2003 Ministry of Health, Malawi National AIDS Commission Publications of the Ministry of Health enjoy
Guidelines for Antiretroviral Therapy
Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe National Medicine and Therapeutics Policy Advisory Committee (NMTPAC) and The AIDS and TB Directorate, Ministry
B.C. HIV/AIDS Drug Treatment Program
B.C. HIV/AIDS Drug Treatment Program Monthly Report January 215 215 BC Centre for Excellence in HIV/AIDS DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS
Presented by: Canadian Working Group on HIV and Rehabilitation
Rehabilitation in the Context of HIV: An Interprofessional Course for Occupational Therapists, Physiotherapists, Speech-Language Pathologists and Audiologists Presented by: Canadian Working Group on HIV
OUTLINE POST EXPOSURE PROPHYLAXIS (PEP) OCCUPATIONAL RISK OF VIRAL TRANSMISSION WITH SHARP INJURY FROM INFECTED SOURCE:
Professional needle stick accidents should be dealt with within 48 hours. An ARC (Aids Reference Centre) or an emergency department must be contacted as soon as possible. OUTLINE POST EXPOSURE PROPHYLAXIS
Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission
No. 310, August 2014 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission This clinical practice guideline has been prepared by the Infectious Diseases
Annual Event 2016 Workshop New to Interreg, where to begin? Évènement annuel 2016 Atelier «Interreg pour les débutants, par où commencer?
Annual Event 2016 Workshop New to Interreg, where to begin? Évènement annuel 2016 Atelier «Interreg pour les débutants, par où commencer?» Contents 1. Why get involved in an Interreg project? 1. Pourquoi
Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV. National Guidelines
Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV National Guidelines National guidelines for post-exposure prophylaxis after non-occupational and occupational exposure
Consolidated guidelines on the use of antiretroviral drugs for treating
TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO
Earlier, safer and simpler antiretroviral therapy can push the HIV epidemic into irreversible decline. -WHO Director-General Dr.
1616 Fort Myer Drive, 12th Floor Arlington, Virginia 22209-3100 USA www.scms.pfscm.org Telephone: +1.571.227.8600 Fax: +1.571.227.8601 SCMS Supply Lines August 2013 Content: Feature Article Trends News
Review When Patients Cannot Take Pills: Antiretroviral Drug Formulations for Managing Adult HIV Infection
IAS USA Topics in Antiviral Medicine Review When Patients Cannot Take Pills: Antiretroviral Drug Formulations for Managing Adult HIV Infection Chessa R. Nyberg, PharmD, Brooke Y. Patterson, PharmD, and
Covered California s 2016 Formularies
Covered California s 2016 Formularies An analysis of the drugs per tier in all 12 health plans that are available for treating and preventing HIV (pp 1 24) and for treating hepatitis B (pp 26 37) and hepatitis
Social and Economic costs of HIV and AIDS. Current issues. Sarah Ann Adomakoh. Costs, cost-effectiveness & Sustainability
Associates for International Development Social and Economic costs of HIV and AIDS Current issues Suite A East Wing ARS Medicae Building No. 14, 6 th Avenue, Belleville St Michael Barbados Tel (246) 429
MINISTRY OF HEALTH GUIDELINES ON USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION RAPID ADVICE
MINISTRY OF HEALTH GUIDELINES ON USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION RAPID ADVICE June 2014 This guideline is under copyright of the National AIDS and STI Control Programme
CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION GENERAL RECOMMENDATIONS:
CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION II. GENERAL RECOMMENDATIONS: The practitioner should conduct a thorough medication history at each visit that includes prescription medications, over-the-counter
HIV Update: Epidemiology and Pathophysiology
HIV Update: Epidemiology and Pathophysiology MATEC Michigan AIDS Research and Education Center Wayne State University School of Medicine (313) 962-2000 matecmichigan.org 1 Epidemiology of the Epidemic:
Generic antiretrovirals in Europe: a blessing or a curse?
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
1/26/2015. Epidemiology of the Epidemic: World. Epidemiology of the Epidemic: United States. HIV Update: Epidemiology and Pathophysiology
HIV Update: Epidemiology and Pathophysiology MATEC Michigan AIDS Research and Education Center Wayne State University School of Medicine (313) 962-2000 matecmichigan.org Epidemiology of the Epidemic: World
Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs
Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs Provinces/Territory Drug Dose Form Alberta British Columbia Manitoba New Brunswick Newfoundland & Labrador
Treating HIV in children with tuberculosis
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
Low quality of care: a constraint to the implementation of community health insurance
Low quality of care: a constraint to the implementation of community health insurance Somé Florent 1, Pfeiffer Karolin 2, Sauerborn Rainer 2 1 Centre de Recherche en Santé de Nouna, Burkina Faso 2 University
National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children
Ministry of Health National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children Edited by: Elly T. Katabira, FRCP Moses R. Kamya, M. Med, MPH, PhD Israel Kalyesubula, M. Med, DTCH
Process Monitoring. 6 th. th Asia-Pacific UN PMTCT Task Force Meeting Kuala Lumpur, Malaysia Nepal Country Team
Process Monitoring 6 th th Asia-Pacific UN PMTCT Task Force Meeting Kuala Lumpur, Malaysia Nepal Country Team Goals of Monitoring and Supervising of the PMTCT program Overall goal is to improve the quality
Module 5: Assuring the Quality of HIV Rapid Testing
Module 10 Inventory: Managing Stocks at the HIV Testing Site Purpose Pre-requisite Modules Learning Objectives Content Outline To equip the participants with necessary knowledge so they can properly manage
ACT. Advocacy for Community Treatment ITPC. Strengthening Community Responses to HIV Treatment and Prevention
ACT toolkit Advocacy for Community Treatment Strengthening Community Responses to HIV Treatment and Prevention ITPC INTERNATIONAL TREATMENT PREPAREDNESS COALITION July 2014 About ITPC ITPC is a worldwide
862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1. Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians
862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1 Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians 2014 862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 2 Recreational Drugs
Women s Health Program Guidelines and Protocols
Women s Health Program Guidelines and Protocols Reducing the Rate of Perinatal HIV Transmission for Mothers and Babies TABLE OF CONTENTS Introduction... 2 Pre-Conception Care... 2 Care for HIV NEGATIVE
Open call for tenders n SCIC C4 2014/01
EUROPEAN COMMISSION DIRECTORATE GENERAL FOR INTERPRETATION RESOURCES AND SUPPORT DIRECTORATE Open call for tenders n SCIC C4 2014/01 Accident and sickness insurance for Conference Interpreting Agents Questions
I. Epidemiology of TB, TB/HIV/AIDS and reciprocal influence of TB and HIV...135 II. Identification of TB/HIV in adults and adolescents...
Contents I. Epidemiology of TB, TB/HIV/AIDS and reciprocal influence of TB and HIV... 135 1. Epidemiology of TB... 135 2. Epidemiology of TB/HIV coinfection... 135 3. Reciprocal influence of HIV and TB...
Offering HIV Post-Exposure Prophylaxis (PEP) Following Non-Occupational Exposures
Offering HIV Post-Exposure Prophylaxis (PEP) Following Non-Occupational Exposures Recommendations for Health Care Providers in the State of California Arnold Schwarzenegger Governor State of California
HAPSAT 2.0 SOFTWARE: HANDS-ON EXERCISE
better systems, better health HAPSAT 2.0 SOFTWARE: HANDS-ON EXERCISE Objectives of this document: Enable users to become familiar with the HAPSAT software and how to populate the tool Enable users to practice
Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania
Antiviral Therapy 13 Suppl 2:77 82 Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania Geofrey R Somi 1, Tabitha Kibuka 2, Karidja Diallo
HIV Post Exposure Prophylaxis Update
HIV Post Exposure Prophylaxis Update Mary Goodspeed, RN, BS 716-898-4713 Coordinator, HIV Clinical Education Initiative Erie County Medical Center, Buffalo, NY PEP Hotline 1-888-448-4911 www.aidscenterecmc.org
SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV
SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV SURVEY REPORT AIDS & TB UNIT Ministry Of Health And Child Welfare Zimbabwe December 2012 1 Table
CURRICULUM VITAE PERSONAL INFORMATION. Scott S. Ubillos, M.D.
CURRICULUM VITAE PERSONAL INFORMATION Name: Scott S. Ubillos, M.D. Office Infectious Disease Associates of Tampa Bay Address: 4 Columbia Drive, Suite 820 Tampa, FL 33606 4729 N. Habana Ave Tampa, Florida
Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
COMPTE RENDU SOMMAIRE SUMMARY RECORD
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR AGRICULTURE AND RURAL DEVELOPMENT Directorate C. Single CMO, economics and analysis of agricultural markets Director Brussels, 05.03.05 ares 978009 (...) D(05)0396
FACULTY OF HEALTH SCIENCES DEPARTMENT OF COMMUNITY MEDICINE
FACULTY OF HEALTH SCIENCES DEPARTMENT OF COMMUNITY MEDICINE Rajesh Shigdel HEL-3950 Master s Thesis in public Health September, 2012 Supervisor: Luai A. Ahmed University of Tromsø ii H E L - 3 9 5 0 M
IgM ELISA. For the quantitative determination of IgM in human serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.
IgM ELISA For the quantitative determination of IgM in human serum and plasma For Research Use Only. Not For Use In Diagnostic Procedures. Please read carefully due to Critical Changes, e.g., Calibrator
CLINICAL GUIDELINES FOR THE MANAGEMENT OF HIV & AIDS IN ADULTS AND ADOLOSCENTS
CLINICAL GUIDELINES FOR THE MANAGEMENT OF HIV & AIDS IN ADULTS AND ADOLOSCENTS National Department of Health South Africa 2010 1 Table of Contents Foreword... 4 Abbreviations... 5 Introduction... 7 1.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
June 29, 2001 / Vol. 50 / No. RR-11 Inside: Continuing Inside: Medical Continuing Education Education for U.S. Examination Physicians and Nurses Recommendations and Reports Updated U.S. Public Health Service
The Role of the Primary Care Clinician in HIV Care
The Role of the Primary Care Clinician in HIV Care Jeffrey Kwong, DNP, ANP-BC, AAHIVS, ACRN, FAANP Columbia University School of Nursing New York, NY New York Nurse Practitioner Association Annual Meeting
DHAPP SENEGAL BACKGROUND. Country Statistics
DHAPP DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM REDUCING THE INCIDENCE OF HIV/AIDS AMONG UNIFORMED PERSONNEL IN SELECTED AFRICAN NATIONS AND BEYOND WINNING BATTLES IN THE WAR AGAINST HIV/AIDS BACKGROUND
Dosage Calculations INTRODUCTION. L earning Objectives CHAPTER
CHAPTER 5 Dosage Calculations L earning Objectives After completing this chapter, you should be able to: Solve one-step pharmaceutical dosage calculations. Set up a series of ratios and proportions to
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Gaetana Sterrantino Azienda Ospedaliero-Universitaria Careggi Infectious diseases, Florence, Italy Background
LABORATORY LOGISTICS HANDBOOK
LABORATORY LOGISTICS HANDBOOK A GUIDE TO DESIGNING AND MANAGING LABORATORY LOGISTICS SYSTEMS JUNE 2009 This publication was produced for review by the U.S. Agency for International Development. It was
MANAGEMENT OF INFANTS BORN TO HIV POSITIVE MOTHERS
MANAGEMENT OF INFANTS BORN TO HIV POSITIVE MOTHERS Introduction Perinatal management of infants born to HIV-infected mothers requires a coordinated multidisciplinary team approach. The consultant leads
Table 1 Comparison of the prices of the 10 best-selling prescription drugs in America with prices in Canada, Great Britain, Australia and Mexico.
Table 1 Comparison of the prices of the 10 best-selling prescription drugs in America with prices in Canada, Great Britain, Australia and Mexico. Drug Condition U.S.A Canada Great Britain Australia Mexico
GARPR Online Reporting Tool
GARPR Online Reporting Tool 0 Narrative Report and Cover Sheet 1) Which institutions/entities were responsible for filling out the indicator forms? a) NAC or equivalent Yes b) NAP Yes c) Others Yes If
Federal Reserve Bank of New York Staff Reports. What Do Drug Monopolies Cost Consumers in Developing Countries?
Federal Reserve Bank of New York Staff Reports What Do Drug Monopolies Cost Consumers in Developing Countries? Rebecca Hellerstein Staff Report no. 530 December 2011 This paper presents preliminary findings
HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
LIQUID DRUG FORMULATIONS. Formulation Status Cost Comments. facilitated access
LIQUID DRUG FORMULATIONS Drug ANTIRETROVIRALS FIXED DOSE COMBINATION PRODUCTS Atripla (efavirenz/ emtricitabine/ tenofovir) No Atripla FDC tablet crushed, dissolved in 5 ml of water and diluted to 20 ml
UK prevalence in pregnancy and risk of transmission
UK prevalence in pregnancy and risk of transmission In 2009 HIV prevalence in the UK among women giving birth was 2.2 per 1000 The majority of these women are from sub-saharan Africa with a prevalence
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis
Please note: These guidelines have been updated. To view the update, please click here. Morbidity and Mortality Weekly Report Recommendations and Reports September 30, 2005 / Vol. 54 / No. RR-9 Updated
Homeopathy as a treatment for HIV and Aids in Swaziland
Homeopathy as a treatment for HIV and Aids in has been estimated to have the highest infection rateof HIV in the world. The demographics from the Homeopathy project database indicate the following: at
Example 3: Dilantin-125 is available as 125 mg/5 ml. Dilantin-125, 0.3 g PO, is ordered. How much should the nurse administer to the patient?
Drug Dosage & IV Rates Calculations Drug Dosage Calculations Drug dosage calculations are required when the amount of medication ordered (or desired) is different from what is available on hand for the
People living. Since the start of the AIDS epidemic, more than 78 million people have been infected with HIV and 39 million have died (1).
THE GAP REPORT 2014 People living with HIV Since the start of the AIDS epidemic, more than 78 million people have been infected with HIV and 39 million have died (1). Acquiring HIV no longer means certain